{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,6]],"date-time":"2026-10-06T14:54:12Z","timestamp":1791298452023,"version":"4.1.0"},"reference-count":14,"publisher":"Springer Science and Business Media LLC","issue":"11","license":[{"start":{"date-parts":[[2016,6,28]],"date-time":"2016-06-28T00:00:00Z","timestamp":1467072000000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Drugs"],"published-print":{"date-parts":[[2016,7]]},"DOI":"10.1007\/s40265-016-0607-y","type":"journal-article","created":{"date-parts":[[2016,6,28]],"date-time":"2016-06-28T09:54:42Z","timestamp":1467107682000},"page":"1147-1152","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":74,"title":["Migalastat: First Global Approval"],"prefix":"10.1007","volume":"76","author":[{"given":"Anthony","family":"Markham","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2016,6,28]]},"reference":[{"key":"607_CR1","unstructured":"Amicus Therapeutics. Amicus Therapeutics announces European Commission approval for Galafold\u2122 (migalastat) in patients with Fabry disease in European Union [media release]. 31 May 2016. http:\/\/www.amicustherapeutics.com ."},{"key":"607_CR2","unstructured":"European Medicines Agency. Galafold 123 mg hard capsules: summary of product characteristics. 2016. http:\/\/www.ema.europa.eu\/ . Accessed 22 June 2016."},{"issue":"4","key":"607_CR3","doi-asserted-by":"crossref","first-page":"717","DOI":"10.1038\/mt.2011.271","volume":"20","author":"ER Benjamin","year":"2012","unstructured":"Benjamin ER, Khanna R, Schilling A, et al. Co-administration with the pharmacological chaperone AT1001 increases recombinant human alpha-galactosidase A tissue uptake and improves substrate reduction in Fabry mice. Mol Ther. 2012;20(4):717\u201326.","journal-title":"Mol Ther."},{"key":"607_CR4","doi-asserted-by":"crossref","first-page":"91","DOI":"10.1186\/1750-1172-7-91","volume":"7","author":"DP Germain","year":"2012","unstructured":"Germain DP, Giugliani R, Hughes DA, et al. Safety and pharmacodynamic effects of a pharmacological chaperone on alpha-galactosidase A activity and globotriaosylceramide clearance in Fabry disease: report from two phase 2 clinical studies. Orphanet J Rare Dis. 2012;7:91.","journal-title":"Orphanet J Rare Dis."},{"issue":"3","key":"607_CR5","doi-asserted-by":"crossref","first-page":"193","DOI":"10.1002\/cpdd.147","volume":"4","author":"FK Johnson","year":"2015","unstructured":"Johnson FK, Mudd PN, Janmohamed SG. Relative bioavailability and the effect of meal type and timing on the pharmacokinetics of migalastat in healthy volunteers. Clin Pharmacol Drug Dev. 2015;4(3):193\u2013202.","journal-title":"Clin Pharmacol Drug Dev"},{"issue":"Suppl 1","key":"607_CR6","first-page":"18","volume":"2","author":"PN Mudd","year":"2013","unstructured":"Mudd PN, Johnson FK, Churchill A. A phase 1 study to investigate the absorption, metabolism and excretion of [14C] migalastat hydrochloride following a single oral administration in healthy volunteers [abstract no. 1699358]. Clin Pharmacol Drug Dev. 2013;2(Suppl 1):18\u20139.","journal-title":"Clin Pharmacol Drug Dev"},{"issue":"Suppl 1","key":"607_CR7","doi-asserted-by":"crossref","first-page":"S85","DOI":"10.1111\/jcpt.12034","volume":"93","author":"FK Johnson","year":"2013","unstructured":"Johnson FK, Mudd PN Jr, Sitaraman S, et al. An open-label study to determine the safety and pharmacokinetics of AT1001 in subjects with impaired renal function and healthy subjects with normal renal function [abstract no. PII-92]. Clin Pharmacol Ther. 2013;93(Suppl 1):S85.","journal-title":"Clin Pharmacol Ther."},{"issue":"Suppl 1","key":"607_CR8","first-page":"S161","volume":"37","author":"ER Benjamin","year":"2014","unstructured":"Benjamin ER, Hamler R, Brignol N, et al. Migalastat reduces plasma globotriaosylsphingosine (lyso-Gb3) in Fabry patients: results from the FACETS phase 3 study [abstract no. P-448]. J Inherit Metab Dis. 2014;37(Suppl 1):S161.","journal-title":"J Inherit Metab Dis."},{"issue":"Suppl 1","key":"607_CR9","first-page":"S56","volume":"38","author":"DP Germain","year":"2015","unstructured":"Germain DP, Bichet DG, Giugliani R, et al. Subjects treated with migalastat continue to demonstrate stable renal function and reduced left ventricular mass index over 3 years in a long-term extension study of Fabry disease [abstract no. O-050]. J Inherit Metab Dis. 2015;38(Suppl 1):S56.","journal-title":"J Inherit Metab Dis."},{"issue":"Suppl 1","key":"607_CR10","first-page":"S43","volume":"37","author":"DP Germain","year":"2014","unstructured":"Germain DP, Bichet D, Giugliani R, et al. Treatment with migalastat results in reduced levels of disease substrate and stable renal function in a phase 3 study of Fabry disease [abstract no. O-060]. J Inherit Metab Dis. 2014;37(Suppl 1):S43.","journal-title":"J Inherit Metab Dis."},{"issue":"2","key":"607_CR11","first-page":"S103","volume":"114","author":"R Schiffmann","year":"2015","unstructured":"Schiffmann R, Bichet DG, Germain DP, et al. Improvement in gastrointestinal symptoms observed in the phase 3 FACETS (AT1001-011) study of migalastat in patients affected with Fabry disease [abstract plus poster]. Mol Genet Metab. 2015;114(2):S103\u20134.","journal-title":"Mol Genet Metab."},{"issue":"2","key":"607_CR12","doi-asserted-by":"crossref","first-page":"S57","DOI":"10.1016\/j.ymgme.2014.12.118","volume":"114","author":"D Hughes","year":"2015","unstructured":"Hughes D, Bichet DG, Giugliani R, et al. Long-term efficacy and safety of migalastat compared to enzyme replacement therapy in Fabry disease: phase 3 study results [abstract no. 115]. Mol Genet Metab. 2015;114(2):S57.","journal-title":"Mol Genet Metab."},{"issue":"1","key":"607_CR13","doi-asserted-by":"crossref","first-page":"86","DOI":"10.1016\/j.ymgme.2013.01.009","volume":"109","author":"R Giugliani","year":"2013","unstructured":"Giugliani R, Waldek S, Germain DP, et al. A phase 2 study of migalastat hydrochloride in females with Fabry disease: selection of population, safety and pharmacodynamic effects. Mol Genet Metab. 2013;109(1):86\u201392.","journal-title":"Mol Genet Metab."},{"issue":"8","key":"607_CR14","doi-asserted-by":"crossref","first-page":"e0134341","DOI":"10.1371\/journal.pone.0134341","volume":"10","author":"DG Warnock","year":"2015","unstructured":"Warnock DG, Bichet DG, Holida M, et al. Oral migalastat HCl leads to greater systemic exposure and tissue levels of active alpha-galactosidase A in fabry patients when co-administered with infused agalsidase. PLoS One. 2015;10(8):e0134341.","journal-title":"PLoS One."}],"container-title":["Drugs"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s40265-016-0607-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s40265-016-0607-y\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s40265-016-0607-y","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2017,6,24]],"date-time":"2017-06-24T17:20:07Z","timestamp":1498324807000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s40265-016-0607-y"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2016,6,28]]},"references-count":14,"journal-issue":{"issue":"11","published-print":{"date-parts":[[2016,7]]}},"alternative-id":["607"],"URL":"https:\/\/doi.org\/10.1007\/s40265-016-0607-y","relation":{},"ISSN":["0012-6667","1179-1950"],"issn-type":[{"value":"0012-6667","type":"print"},{"value":"1179-1950","type":"electronic"}],"subject":[],"published":{"date-parts":[[2016,6,28]]}}}